FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation.
Brinkmann
V
V
Transplantation Research, Novartis Pharma AG, Transplantation Research, WSJ-386.1.25, CH-4002 Basel, Switzerland. volker.brinkmann@pharma.novartis.com
Pinschewer
D
D
Chiba
K
K
Feng
L
L
D002465:Cell Movement / Q000187:drug effects; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000187:drug effects; D016131:Lymphocyte Subsets / Q000187:drug effects* / Q000276:immunology; D016377:Organ Transplantation; D011409:Propylene Glycols / Q000009:adverse effects / Q000494:pharmacology*; D020011:Protective Agents / Q000494:pharmacology; D013110:Sphingosine / Q000031:analogs & derivatives; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D020011:Protective Agents; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine